Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Yoon

Showing results (1311-1320 of 1,392) with videos related to

Pageof 140
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Comparison of diameter and perimeter methods for tumor volume calculationA G Sorensen, S Patel, C Harmath, et al.
Structural Dynamics (Melville, N.Y.)|January 23, 2016
Electronic damage in S atoms in a native protein crystal induced by an intense X-ray free-electron laser pulseL Galli, S-K Son, M Klinge, et al.
ESMO Open|January 11, 2025
Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer studyG Ku, G M Haag, H Park, et al.
ESMO Open|August 27, 2022
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort AD V T Catenacci, Y-K Kang, H H Yoon, et al.
Biorxiv : the Preprint Server for Biology|January 16, 2026
Stepwise DNA unwinding gates TnpB genome-editing activityZehan Zhou, Iren Saffarian-Deemyad, Honglue Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal JunctionMojun Zhu, Chunhua Chen, Nathan R Foster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2015
Association between information provision and decisional conflict in cancer patientsJ A Sim, J S Shin, S M Park, et al.
The Lancet. Oncology|October 20, 2022
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trialGeorgina V Long, Jason J Luke, Muhammad A Khattak, et al.
The Lancet Regional Health. Western Pacific|February 14, 2023
Gender-associated cardiometabolic risk profiles and health behaviors in patients with type 2 diabetes: a cross-sectional analysis of the Joint Asia Diabetes Evaluation (JADE) programLee-Ling Lim, Eric S H Lau, Alice P S Kong, et al.
JAMA Oncology|March 16, 2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 TrialCharles S Fuchs, Toshihiko Doi, Raymond W Jang, et al.
Pageof 140

Showing results (1311-1320 of 1,392) with videos related to

Sort By:
Pageof 140
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Comparison of diameter and perimeter methods for tumor volume calculationA G Sorensen, S Patel, C Harmath, et al.
Structural Dynamics (Melville, N.Y.)|January 23, 2016
Electronic damage in S atoms in a native protein crystal induced by an intense X-ray free-electron laser pulseL Galli, S-K Son, M Klinge, et al.
ESMO Open|January 11, 2025
Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer studyG Ku, G M Haag, H Park, et al.
ESMO Open|August 27, 2022
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort AD V T Catenacci, Y-K Kang, H H Yoon, et al.
Biorxiv : the Preprint Server for Biology|January 16, 2026
Stepwise DNA unwinding gates TnpB genome-editing activityZehan Zhou, Iren Saffarian-Deemyad, Honglue Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal JunctionMojun Zhu, Chunhua Chen, Nathan R Foster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2015
Association between information provision and decisional conflict in cancer patientsJ A Sim, J S Shin, S M Park, et al.
The Lancet. Oncology|October 20, 2022
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trialGeorgina V Long, Jason J Luke, Muhammad A Khattak, et al.
The Lancet Regional Health. Western Pacific|February 14, 2023
Gender-associated cardiometabolic risk profiles and health behaviors in patients with type 2 diabetes: a cross-sectional analysis of the Joint Asia Diabetes Evaluation (JADE) programLee-Ling Lim, Eric S H Lau, Alice P S Kong, et al.
JAMA Oncology|March 16, 2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 TrialCharles S Fuchs, Toshihiko Doi, Raymond W Jang, et al.
Pageof 140